MDXXF (Pharmala Biotech Holdings) PEG Ratio: N/A (As of Jul. 11, 2026)


MDXXF Pharmala Biotech Holdings Inc MDXXF
35 GF Score
Price $0.11
GF Value $0.15
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharmala Biotech Holdings PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Pharmala Biotech Holdings's PE Ratio without NRI is 0.00. Pharmala Biotech Holdings's 5-Year EBITDA growth rate is 0.00%. Therefore, Pharmala Biotech Holdings's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Pharmala Biotech Holdings's PEG Ratio or its related term are showing as below:



MDXXF's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.915
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Pharmala Biotech Holdings  (OTCPK:MDXXF) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Pharmala Biotech Holdings PEG Ratio Related Terms


Pharmala Biotech Holdings PEG Ratio Historical Data

* Premium members only.

The historical data trend for Pharmala Biotech Holdings's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings PEG Ratio Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
PEG Ratio
0.00 0.00 0.00 0.00 0.00

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MDXXF vs VRTX, REGN, ALNY: PEG Ratio Comparison

For the Biotechnology subindustry, Pharmala Biotech Holdings's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's PEG Ratio falls into.


MDXXF
35GF Score
Pharmala Biotech Holdings Inc MDXXF
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmala Biotech Holdings PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Pharmala Biotech Holdings's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued. The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15. GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.

Key valuation signals for MDXXF:

  • PEG Ratio: N/A
  • GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
  • GF Score™: 35/100 with 1 warning sign

No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmala Biotech Holdings Business Description

Other Exchanges MDMA:Canada
Address 1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score

Get the complete analysis for MDXXF

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.15
GF Value